Could adding chemo to tarlatamab overcome resistance in lung cancer?

NCT ID NCT07699237

Not yet recruiting Disease control Sponsor: University of Cologne Source: ClinicalTrials.gov ↗

First seen Jul 13, 2026 · Last updated Jul 14, 2026 · Updated 1 time

Summary

This phase 2 trial is testing whether giving platinum-based chemotherapy (carboplatin and etoposide) together with the immunotherapy tarlatamab can help patients with advanced small-cell lung cancer whose disease has worsened while on tarlatamab alone. The study enrolls about 54 adults whose cancer was previously sensitive to platinum chemo. Researchers hope the combination may work better than switching treatments one after the other, by boosting the immune response and breaking down tumor defenses.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Carboplatin and Etoposide (chemotherapy) plus Tarlatamab (immunotherapy)
What this could lead to: If successful, this combination approach could offer a new treatment option for patients whose lung cancer progresses while on tarlatamab, potentially improving outcomes by using both therapies together.
What could go wrong: This is a phase 2 trial with only 54 participants, so results are preliminary. The combination may increase side effects, and it is not yet known if it works better than sequential therapy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates